If you could invest $56 billion each year in improving health care for older adults, how would you spend it? On a hugely expensive medication with questionable efficacy — or something else? This isn’t an abstract question. Aduhelm, a new Alzheimer’s drug approved by the Food and Drug Administration last month, could be prescribed to 1 million to 2 million patients a year, even if conservative criteria were used, according to Biogen and Eisai, the companies behind the drug. The total annual price tag would come to $56 billion if the average list price, $56,000, is applied to the lower end of the companies’ estimate. That’s a huge sum by any measure — more than the annual b
Hence then, the article about paying billions for controversial alzheimer s drug how about funding this instead was published today ( ) and is available onKHN ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Paying Billions for Controversial Alzheimer’s Drug? How About Funding This Instead? )